Akebia Therapeutics (AKBA) Current Deferred Revenue (2016 - 2026)

Akebia Therapeutics (AKBA) has 11 years of Current Deferred Revenue data on file, last reported at $4.5 million in Q1 2026.

• Current Deferred Revenue for Q1 2026 came in at $4.5 million, up 262.29% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.5 million (up 262.29% YoY), and the FY2025 annual result was $2.7 million, changed N/A from the prior year.
• Current Deferred Revenue advanced to $4.5 million in Q1 2026 per AKBA's latest filing, from $2.7 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $75.8 million in Q1 2022 and troughed at $1.2 million in Q1 2025.
• A 5-year average of $31.8 million and a median of $43.3 million in 2023 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2025 and 2026: Current Deferred Revenue sank 97.18% in 2025, then surged 262.29% in 2026.
• A 5-year view of Current Deferred Revenue shows it stood at $47.0 million in 2022, then decreased by 7.95% to $43.3 million in 2023, then changed by 0.0% to $43.3 million in 2024, then tumbled by 93.81% to $2.7 million in 2025, then soared by 67.7% to $4.5 million in 2026.
• Business Quant data shows AKBA's Current Deferred Revenue at $4.5 million in Q1 2026, $2.7 million in Q4 2025, and $3.9 million in Q3 2025.